We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Microbiological Tests Detect AmpC β-Lactamase Producing Bacteria

By LabMedica International staff writers
Posted on 01 Jun 2011
A modification of existing tests allows the detection of plasmid-mediated AmpC-producing Escherichia coli and Klebsiella pneumoniae that are not readily identified in clinical laboratories. More...


Antibiotic susceptibility by standard microbiological procedures can be carried out on automatic platforms and further tested by the modified Hodge test (MHT) to ascertain the presence or absence Gram-negative bacteria producing AmpC ß-lactamase.

Scientists at the University of Florida (Gainesville, FL, USA), tested between January 2007 and June 2008, 753 gram-negative bloodstream isolates for AmpC by using the ethylenediaminetetraacetic acid (EDTA) synergy disk test and the MHT on 172 samples and the MHT alone on the other 581 isolates. All isolates were identified and tested for antibiotic susceptibility by standard microbiological procedures using MicroScan (Siemens HealthCare, Deerfield Park, IL, USA).

The 26 patients of the AmpC group were selected on the basis on the degree of AmpC positivity on the MHT, with a growth of the indicator strain along the test isolate streak of 3 mm or more. In the control group, there were had 52 isolates that had no or minimal distortion of the cefoxitin zone and therefore were considered negative. These non-AmpC producers were matched in a 2:1 ratio by bacterial species. Mortality within 30 days was reported in 9% of the AmpC group and in 6% for the control group. Patients in the AmpC group were significantly more likely to be in an intensive care unit and to have been intubated than patients in the control group were at the time of the positive blood culture. Moreover, patients in the AmpC group were significantly less likely to have received an effective antibiotic within the first 48 hours after the blood culture was obtained than were patients in the control group.

The authors concluded that there was a very good correlation between the EDTA disk test and the MHT in a subset of their isolates, although the correlation was not perfect and the EDTA disk test identified more positives. The MHT and the EDTA disk test did not seem to identify a subset of patients at risk for a poor outcome from AmpC with the antibiotic use patterns in their hospital. The study was published in April 2011 in the American Journal of Clinical Pathology.

Related Links:
University of Florida
Siemens HealthCare




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.